Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru, a first-in-class treatment for fibrodysplasia ossificans progressiva. The approval is based on positive Phase 3 trial results. Analysts discuss how this new drug may impact Regeneron's investment narrative, alongside existing key products like EYLEA HD and Dupixent. The company projects $19.4B revenue and $6.0B earnings by 2029, with optimistic analysts suggesting higher figures.